Adial Pharmaceuticals Management
Management criteria checks 4/4
Adial Pharmaceuticals' CEO is Cary Claiborne, appointed in Aug 2022, has a tenure of 2.42 years. total yearly compensation is $801.62K, comprised of 58.1% salary and 41.9% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $64.48K. The average tenure of the management team and the board of directors is 2.4 years and 7.5 years respectively.
Key information
Cary Claiborne
Chief executive officer
US$801.6k
Total compensation
| CEO salary percentage | 58.1% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.4yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Adial Clinical Trial: A Fluff Or A Win?
Aug 22Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Aug 16Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
Jun 21Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate
Jan 11Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$13m |
| Jun 30 2024 | n/a | n/a | -US$12m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$802k | US$466k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$1m | US$357k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$688k | US$15k | -US$19m |
Compensation vs Market: Cary's total compensation ($USD801.62K) is about average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Cary's compensation has been consistent with company performance over the past year.
CEO
Cary Claiborne (64 yo)
2.4yrs
Tenure
US$801,621
Compensation
Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.4yrs | US$801.62k | 0.95% $ 64.5k | |
| COO & Director | less than a year | US$261.93k | 0.0055% $ 370.9 | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Legal Officer | 4yrs | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data | |
| Controller | 4yrs | no data | no data |
2.4yrs
Average Tenure
62yo
Average Age
Experienced Management: ADIL's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.2yrs | US$801.62k | 0.95% $ 64.5k | |
| COO & Director | 7.5yrs | US$261.93k | 0.0055% $ 370.9 | |
| Chairman & Lead Independent Director | 8.8yrs | US$60.22k | 0.013% $ 870.9 | |
| Independent Director | 10.3yrs | US$56.22k | 0.21% $ 14.4k | |
| Independent Director | 10.3yrs | US$53.22k | 0% $ 0 | |
| Independent Director | 9.9yrs | US$59.22k | 0% $ 0 | |
| Chairperson of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Member of the Scientific Advisory Board | 6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6yrs | no data | no data |
7.5yrs
Average Tenure
62yo
Average Age
Experienced Board: ADIL's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 23:08 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adial Pharmaceuticals, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Theodore O'Neill | Litchfield Hills Research, LLC |